Differentially Expressed MicroRNAs in Allergic Asthma Target Genes underlying Airway Hyper-Responsiveness and Goblet Cell Hyperplasia (136.22)

Abstract

Abstract Asthma is an allergic disease that results in the obstruction of airways as a result of goblet cell hyperplasia and airway hyper-reactivity (AHR). Broad-spectrum P2-receptor antagonists and glucocorticoids are commonly used therapeutic agents for this disease. Niflumic acid (NA), an inhibitor of calcium-activated chloride channels is used to overcome corticosteroid-resistant asthma. Using Next Generation Sequencing, we dissected the asthma-related small RNAome in the lung before and after (FC) allergen challenge. We find a significant induction of microRNAs in FC from 40% to 74% suggesting an important role for miRNAs in asthma. Also, we uncovered 460 miRNA-up:mRNA-down and 17 miRNA-down:mRNA-up pairs that are significantly correlated in naïve and FC lung. The latter category contains a number of key genes induced during asthma and include miR-106b:P2X, miR-205:P2Y, miR-145:CLCA3 and miR-133a:GM-CSF. We also uncovered two novel miRNAs Asth-miR-1 and Asth-miR-2. Asth-miR-1 is predicted to target Toll-like receptor (TLR) adaptor TIRAP and IRAK which associates to activate NF-Kb, AP-1 and IRFs, and under some conditions, induce allergic lung disease. Asth-miR-2 is predicted to target ryanodine receptor 2 (RyR) that mediates Ca2+ release that induces airway smooth muscle contraction and bronchoconstriction. The integration of miR-106b, 205, 145 a, 133a and Asth-miR-1 and Asth-miR-1 2 with current therapies can potentially significantly enhance the efficacy and specificity of drugs used to combat asthma.